Influence of baseline renal function and dose reduction of nephrotoxic chemotherapeutic agents on the outcome of metastatic urothelial carcinoma: A retrospective study
Authors:
- 29 November 2011
- journal article
- research article
- Published by Wiley in International Journal of Urology
- Vol. 19 (2) , 110-116
Abstract
Objectives: To investigate the influence of baseline renal function and dose reduction of chemotherapeutic agents on the outcome of metastatic urothelial carcinoma patients with renal impairment. Methods: A total of 57 patients with metastatic urothelial carcinoma treated by systemic chemotherapy were included in the present study. The 24 h‐creatinine clearance was measured before each cycle and dose reduction was carried out according to our guidelines. Patients were divided into two groups according to baseline 24 h‐creatinine clearance: fit group (60 mL/min/1.48 m2≤) and unfit group (60 mL/min/1.48 m2>). Clinical characteristics and final outcomes were compared between the two groups. Results: There was no significant difference in the total number of chemotherapy cycles of each patient between the two groups (fit group: median 5; unfit group: median 4; P = 0.7466), although dose reduction was carried out significantly more often in the unfit group than in the fit group during treatment (fit group: median 0 cycles; unfit group: median 3.5 cycles; P = 0.0016). Overall, the median survival was 16 months. There was a significant survival difference between the two groups (fit group: median 17 months; unfit group: median 10 months; P = 0.0419). On multivariate analyses, impaired renal function at the baseline remained an adverse factor (HR 2.27, P = 0.01). Conclusions: “Unfit” was a poor prognostic factor for metastatic urothelial carcinoma. The dose reduction strategy contributed to continuous treatment in the unfit group. However, its contribution to the prognosis of unfit patients is uncertain.Keywords
This publication has 13 references indexed in Scilit:
- Changes in Renal Function Following Nephroureterectomy May Affect the Use of Perioperative ChemotherapyEuropean Urology, 2010
- Impact of Multimodal Treatment on Survival in Patients with Metastatic Urothelial CancerEuropean Urology, 2007
- Cancer Incidence and Incidence Rates in Japan in 2000: Estimates Based on Data from 11 Population-Based Cancer RegistriesJapanese Journal of Clinical Oncology, 2006
- Impact of renal impairment on eligibility for adjuvant cisplatin‐based chemotherapy in patients with urothelial carcinoma of the bladderCancer, 2006
- Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology GroupUrology, 2004
- A feasibility study of carboplatin with fixed dose of gemcitabine in ‘unfit’ patients with advanced bladder cancerEuropean Journal of Cancer, 2001
- Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III StudyJournal of Clinical Oncology, 2000
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal functionCancer Treatment Reviews, 1995
- Reporting results of cancer treatmentCancer, 1981